April 10, 2025 8:20am
Volatility and uncertainty are here to stay initially helped by a bit by tantalizing time pushing headlines
I didn’t take a toke, NOT anticipating a temporary high
News: BrainStorm Cell Therapeutics (BCLI +$0.13 pre-open) submitted an IN) amendment to the FDA for NurOwn®, it's autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS). This important milestone sets the stage for the initiation of CLI's highly anticipated P3b clinical trial, which has been designed in collaboration with the FDA under a Special Protocol Assessment (SPA). The SPA agreement confirms that the P 3b trial design and statistical analysis plan is in line with the FDA's expectations, validating its potential to support a future Biologics License Application (BLA).
Breaking News: Consumer price inflation (CPI) eased more than expected in March. The consumer price index, a broad measure of goods and services costs across the U.S. economy, fell 0.1% in March, putting the 12-month inflation rate at 2.4%. Excluding food and energy, so-called core inflation ran at a 2.8% annual rate, having increased 0.1% for the month. That was the lowest rate for core inflation since March 2021.
Pre-open Indications: 5 Negative and 1 Positive Indications
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!
Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: Abra-Karaba, presto pronto; sector’s up, up and away … https://www.regmedinvestors.com/articles/13873
RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812
Thursday: The pre-open Dow futures are DOWN -1.04% or (-423 points), the S&P futures DOWN -1.37% or (-75 points) and the Nasdaq futures are DOWN -1.77% or (-341 points)
- Stock futures fell on Thursday, 4/10
- European markets rose sharply at their open,
- Asia-Pacific markets rose Thursday
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Wednesday: The Dow closed UP +2,962.86 points or +7.87%, the S&P closed UP +474.13 points or +9.52% while the Nasdaq close UP +1,857.06 points or +12.16%
During Wednesday’s session, there was an unusual trading volume of around 30 billion shares, the highest level in history, as per records dating back 18 years. <CNBC>
Economic Data Docket: March’s consumer price index reading and weekly jobless claims, due
Q2- April – 5 negative and 2 positive closes
- Q1/25 – March, 10 positive and 11 negative closes
- February – 12 holiday, 11 negative and 7 positive closes
- January - 2 holidays, 1 market close, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
- Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the … econs, it is still a mix of ups, downs and just uncertainty
Although … trending tickers
Negative Indications:
AxoGen (AXGN) closed up +0.40 after Friday’s -$0.82 with a negative -$0.22 or -1.31% pre-market
BioLife Solutions (BLFS) closed up +$$2.15 with a negative -$1.02 or -4.48%
Beam Therapeutics (BEAM) closed up +$1.83 with a negative -$0.24 or -1.47% pre-market
CRISPR Therapeutics (CRSP) closed up +$3.62 with a negative -$1.03 or -2.95%
Moderna (MRNA) close up +$2.03 with a negative 0.52 or -1.95% pre-open
The BOTTOM LINE: I am ... in a RISK-On mood!
I believe cell and gene therapy equities will be pulling back after soaring yesterday on the news.
Also, the 10-year Treasury yield, which affects borrowing costs on all sorts of loans, is falling after spiking Wednesday.
Brace ourself for more economics and their down trending affect?
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
